Clinical Trial Update: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 safety and tolerability study of MEDI6469 with therapeutic immune agents or monoclonal antibodies in patients with advanced solid tumors and aggressi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• MEDI6469

Snippet

Sponsor: MedImmune LLC | Conditions: Advanced Solid Tumors, Aggressive B-cell Lymphomas | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-05-08